Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 652 entries
Sorted by: Best Match Show Resources per page
Lipidomics of human umbilical cord serum: identification of unique sterol sulfates.

Future science OA

Wood PL, Siljander H, Knip M.
PMID: 28883994
Future Sci OA. 2017 Apr 05;3(3):FSO193. doi: 10.4155/fsoa-2017-0012. eCollection 2017 Aug.

AIM: There are currently limited lipidomics data for human umbilical cord blood. Therefore, the lipidomes of cord sera from six newborns and sera from six nonpregnant females were compared.MATERIALS & METHODS: Sera lipidomics analyses were conducted using a high-resolution...

Cite
Wood PL, Siljander H, Knip M. Lipidomics of human umbilical cord serum: identification of unique sterol sulfates. Future Sci OA. 2017;3(3):FSO193doi: 10.4155/fsoa-2017-0012.
Wood, P. L., Siljander, H., & Knip, M. (2017). Lipidomics of human umbilical cord serum: identification of unique sterol sulfates. Future science OA, 3(3), FSO193. https://doi.org/10.4155/fsoa-2017-0012
Wood, Paul L, et al. "Lipidomics of human umbilical cord serum: identification of unique sterol sulfates." Future science OA vol. 3,3 (2017): FSO193. doi: https://doi.org/10.4155/fsoa-2017-0012
Wood PL, Siljander H, Knip M. Lipidomics of human umbilical cord serum: identification of unique sterol sulfates. Future Sci OA. 2017 Apr 05;3(3):FSO193. doi: 10.4155/fsoa-2017-0012. eCollection 2017 Aug. PMID: 28883994; PMCID: PMC5583693.
Copy Download .nbib Format: NLM
Integrating the glioblastoma microenvironment into engineered experimental models.

Future science OA

Xiao W, Sohrabi A, Seidlits SK.
PMID: 28883992
Future Sci OA. 2017 Mar 24;3(3):FSO189. doi: 10.4155/fsoa-2016-0094. eCollection 2017 Aug.

Glioblastoma (GBM) is the most lethal cancer originating in the brain. Its high mortality rate has been attributed to therapeutic resistance and rapid, diffuse invasion - both of which are strongly influenced by the unique microenvironment. Thus, there is...

Cite
Xiao W, Sohrabi A, Seidlits SK. Integrating the glioblastoma microenvironment into engineered experimental models. Future Sci OA. 2017;3(3):FSO189doi: 10.4155/fsoa-2016-0094.
Xiao, W., Sohrabi, A., & Seidlits, S. K. (2017). Integrating the glioblastoma microenvironment into engineered experimental models. Future science OA, 3(3), FSO189. https://doi.org/10.4155/fsoa-2016-0094
Xiao, Weikun, et al. "Integrating the glioblastoma microenvironment into engineered experimental models." Future science OA vol. 3,3 (2017): FSO189. doi: https://doi.org/10.4155/fsoa-2016-0094
Xiao W, Sohrabi A, Seidlits SK. Integrating the glioblastoma microenvironment into engineered experimental models. Future Sci OA. 2017 Mar 24;3(3):FSO189. doi: 10.4155/fsoa-2016-0094. eCollection 2017 Aug. PMID: 28883992; PMCID: PMC5583655.
Copy Download .nbib Format: NLM
Strategies to enhance graphic and results interpretation of a regression-based approach for method comparison studies.

Future science OA

Sotgia S, Mangoni AA, Pintus G, Carru C, Zinellu A.
PMID: 28883995
Future Sci OA. 2017 Apr 21;3(3):FSO0194. doi: 10.4155/fsoa-2017-0004. eCollection 2017 Aug.

To improve the effectiveness of a previous regression-based approach for the assessment of the agreement between different analytical methods, two modifications/integrations to the original scheme by means of log10 transformation of data and implementation of inherent combined imprecision are...

Cite
Sotgia S, Mangoni AA, Pintus G, et al. Strategies to enhance graphic and results interpretation of a regression-based approach for method comparison studies. Future Sci OA. 2017;3(3):FSO0194doi: 10.4155/fsoa-2017-0004.
Sotgia, S., Mangoni, A. A., Pintus, G., Carru, C., & Zinellu, A. (2017). Strategies to enhance graphic and results interpretation of a regression-based approach for method comparison studies. Future science OA, 3(3), FSO0194. https://doi.org/10.4155/fsoa-2017-0004
Sotgia, Salvatore, et al. "Strategies to enhance graphic and results interpretation of a regression-based approach for method comparison studies." Future science OA vol. 3,3 (2017): FSO0194. doi: https://doi.org/10.4155/fsoa-2017-0004
Sotgia S, Mangoni AA, Pintus G, Carru C, Zinellu A. Strategies to enhance graphic and results interpretation of a regression-based approach for method comparison studies. Future Sci OA. 2017 Apr 21;3(3):FSO0194. doi: 10.4155/fsoa-2017-0004. eCollection 2017 Aug. PMID: 28883995; PMCID: PMC5583665.
Copy Download .nbib Format: NLM
Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites.

Future science OA

Galluzzi L, Diotallevi A, Magnani M.
PMID: 28883998
Future Sci OA. 2017 May 12;3(3):FSO198. doi: 10.4155/fsoa-2017-0020. eCollection 2017 Aug.

Perturbations of the physiological status of the endoplasmic reticulum (ER) trigger a specific response known as the ER stress response or unfolded protein response (UPR). In mammalian cells, the UPR is mediated by three ER transmembrane proteins (IRE1, PERK...

Cite
Galluzzi L, Diotallevi A, Magnani M. Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites. Future Sci OA. 2017;3(3):FSO198doi: 10.4155/fsoa-2017-0020.
Galluzzi, L., Diotallevi, A., & Magnani, M. (2017). Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites. Future science OA, 3(3), FSO198. https://doi.org/10.4155/fsoa-2017-0020
Galluzzi, Luca, et al. "Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites." Future science OA vol. 3,3 (2017): FSO198. doi: https://doi.org/10.4155/fsoa-2017-0020
Galluzzi L, Diotallevi A, Magnani M. Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites. Future Sci OA. 2017 May 12;3(3):FSO198. doi: 10.4155/fsoa-2017-0020. eCollection 2017 Aug. PMID: 28883998; PMCID: PMC5583660.
Copy Download .nbib Format: NLM
Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics.

Future science OA

Mukherjee S, Patra CR.
PMID: 28884002
Future Sci OA. 2017 May 26;3(3):FSO203. doi: 10.4155/fsoa-2017-0035. eCollection 2017 Aug.

No abstract available.

Cite
Mukherjee S, Patra CR. Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics. Future Sci OA. 2017;3(3):FSO203doi: 10.4155/fsoa-2017-0035.
Mukherjee, S., & Patra, C. R. (2017). Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics. Future science OA, 3(3), FSO203. https://doi.org/10.4155/fsoa-2017-0035
Mukherjee, Sudip, and Patra, Chitta Ranjan. "Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics." Future science OA vol. 3,3 (2017): FSO203. doi: https://doi.org/10.4155/fsoa-2017-0035
Mukherjee S, Patra CR. Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics. Future Sci OA. 2017 May 26;3(3):FSO203. doi: 10.4155/fsoa-2017-0035. eCollection 2017 Aug. PMID: 28884002; PMCID: PMC5583654.
Copy Download .nbib Format: NLM
Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period.

Future science OA

Abu Hassan SO, Nielsen DL, Tuxen MK, Petersen PH, Sölétormos G.
PMID: 28884012
Future Sci OA. 2017 Jul 18;3(3):FSO216. doi: 10.4155/fsoa-2017-0023. eCollection 2017 Aug.

AIM: To investigate seven CA125 criteria to monitor progressive ovarian cancer among patients with stage IC-IV disease.MATERIALS & METHODS: Four criteria were used to asses CA125 increments starting from concentrations ≥35 U/ml and three criteria to asses increments starting...

Cite
Abu Hassan SO, Nielsen DL, Tuxen MK, et al. Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period. Future Sci OA. 2017;3(3):FSO216doi: 10.4155/fsoa-2017-0023.
Abu Hassan, S. O., Nielsen, D. L., Tuxen, M. K., Petersen, P. H., & Sölétormos, G. (2017). Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period. Future science OA, 3(3), FSO216. https://doi.org/10.4155/fsoa-2017-0023
Abu Hassan, Suher O, et al. "Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period." Future science OA vol. 3,3 (2017): FSO216. doi: https://doi.org/10.4155/fsoa-2017-0023
Abu Hassan SO, Nielsen DL, Tuxen MK, Petersen PH, Sölétormos G. Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period. Future Sci OA. 2017 Jul 18;3(3):FSO216. doi: 10.4155/fsoa-2017-0023. eCollection 2017 Aug. PMID: 28884012; PMCID: PMC5583662.
Copy Download .nbib Format: NLM
Exploring and validating physicochemical properties of mangiferin through GastroPlus.

Future science OA

Khurana RK, Kaur R, Kaur M, Kaur R, Kaur J, Kaur H, Singh B.
PMID: 28344830
Future Sci OA. 2017 Jan 16;3(1):FSO167. doi: 10.4155/fsoa-2016-0055. eCollection 2017 Mar.

AIM: Mangiferin (Mgf), a promising therapeutic polyphenol, exhibits poor oral bioavailability. Hence, apt delivery systems are required to facilitate its gastrointestinal absorption. The requisite details on its physicochemical properties have not yet been well documented in literature. Accordingly, in...

Cite
Khurana RK, Kaur R, Kaur M, et al. Exploring and validating physicochemical properties of mangiferin through GastroPlus. Future Sci OA. 2017;3(1):FSO167doi: 10.4155/fsoa-2016-0055.
Khurana, R. K., Kaur, R., Kaur, M., Kaur, R., Kaur, J., Kaur, H., & Singh, B. (2017). Exploring and validating physicochemical properties of mangiferin through GastroPlus. Future science OA, 3(1), FSO167. https://doi.org/10.4155/fsoa-2016-0055
Khurana, Rajneet Kaur, et al. "Exploring and validating physicochemical properties of mangiferin through GastroPlus." Future science OA vol. 3,1 (2017): FSO167. doi: https://doi.org/10.4155/fsoa-2016-0055
Khurana RK, Kaur R, Kaur M, Kaur R, Kaur J, Kaur H, Singh B. Exploring and validating physicochemical properties of mangiferin through GastroPlus. Future Sci OA. 2017 Jan 16;3(1):FSO167. doi: 10.4155/fsoa-2016-0055. eCollection 2017 Mar. PMID: 28344830; PMCID: PMC5351510.
Copy Download .nbib Format: NLM
[No title available]

Future science OA

Meijer TG, Naipal KA, Jager A, van Gent DC.
PMID: 28670477
Future Sci OA. 2017 Mar 27;3(2):FSO190. doi: 10.4155/fsoa-2017-0003. eCollection 2017 Jun.

Optimal patient stratification is of utmost importance in the era of personalized medicine. Prediction of individual treatment responses by functional

Cite
Meijer TG, Naipal KA, Jager A, et al. . Future Sci OA. 2017;3(2):FSO190doi: 10.4155/fsoa-2017-0003.
Meijer, T. G., Naipal, K. A., Jager, A., & van Gent, D. C. (2017). . Future science OA, 3(2), FSO190. https://doi.org/10.4155/fsoa-2017-0003
Meijer, Titia G, et al. "." Future science OA vol. 3,2 (2017): FSO190. doi: https://doi.org/10.4155/fsoa-2017-0003
Meijer TG, Naipal KA, Jager A, van Gent DC. . Future Sci OA. 2017 Mar 27;3(2):FSO190. doi: 10.4155/fsoa-2017-0003. eCollection 2017 Jun. PMID: 28670477; PMCID: PMC5481868.
Copy Download .nbib Format: NLM
Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature.

Future science OA

Khier S, Lohan L.
PMID: 29682327
Future Sci OA. 2018 Feb 23;4(4):FSO295. doi: 10.4155/fsoa-2017-0140. eCollection 2018 Apr.

Circulating cell-free DNA is considered as one of the major breakthroughs in the field of innovative diagnosis, used as a liquid biopsy. The kinetic parameters of a biomarker are mandatory to assess its usefulness as a diagnostic tool. Obtaining...

Cite
Khier S, Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. 2018;4(4):FSO295doi: 10.4155/fsoa-2017-0140.
Khier, S., & Lohan, L. (2018). Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future science OA, 4(4), FSO295. https://doi.org/10.4155/fsoa-2017-0140
Khier, Sonia, and Lohan, Laura. "Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature." Future science OA vol. 4,4 (2018): FSO295. doi: https://doi.org/10.4155/fsoa-2017-0140
Khier S, Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. 2018 Feb 23;4(4):FSO295. doi: 10.4155/fsoa-2017-0140. eCollection 2018 Apr. PMID: 29682327; PMCID: PMC5905581.
Copy Download .nbib Format: NLM
Accurate identification of clinically important .

Future science OA

Vijayakumar S, Biswas I, Veeraraghavan B.
PMID: 31285840
Future Sci OA. 2019 Jun 27;5(6):FSO395. doi: 10.2144/fsoa-2018-0127.

No abstract available.

Cite
Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important . Future Sci OA. 2019;5(6):FSO395doi: 10.2144/fsoa-2018-0127.
Vijayakumar, S., Biswas, I., & Veeraraghavan, B. (2019). Accurate identification of clinically important . Future science OA, 5(6), FSO395. https://doi.org/10.2144/fsoa-2018-0127
Vijayakumar, Saranya, et al. "Accurate identification of clinically important ." Future science OA vol. 5,6 (2019): FSO395. doi: https://doi.org/10.2144/fsoa-2018-0127
Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important . Future Sci OA. 2019 Jun 27;5(6):FSO395. doi: 10.2144/fsoa-2018-0127. PMID: 31285840; PMCID: PMC6609899.
Copy Download .nbib Format: NLM
The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting.

Future science OA

Blair IA, Farmer J, Hersch S, Larkindale J, Lynch DR, Napierala J, Napierala M, Payne RM, Subramony SH.
PMID: 31285843
Future Sci OA. 2019 Jun 28;5(6):FSO398. doi: 10.2144/fsoa-2019-0026.

The 2018 FARA Biomarker Meeting highlighted the current state of development of biomarkers for Friedreich's ataxia. A mass spectroscopy assay to sensitively measure mature frataxin (reduction of which is the root cause of disease) is being developed. Biomarkers to...

Cite
Blair IA, Farmer J, Hersch S, et al. The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting. Future Sci OA. 2019;5(6):FSO398doi: 10.2144/fsoa-2019-0026.
Blair, I. A., Farmer, J., Hersch, S., Larkindale, J., Lynch, D. R., Napierala, J., Napierala, M., Payne, R. M., & Subramony, S. H. (2019). The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting. Future science OA, 5(6), FSO398. https://doi.org/10.2144/fsoa-2019-0026
Blair, Ian A, et al. "The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting." Future science OA vol. 5,6 (2019): FSO398. doi: https://doi.org/10.2144/fsoa-2019-0026
Blair IA, Farmer J, Hersch S, Larkindale J, Lynch DR, Napierala J, Napierala M, Payne RM, Subramony SH. The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting. Future Sci OA. 2019 Jun 28;5(6):FSO398. doi: 10.2144/fsoa-2019-0026. PMID: 31285843; PMCID: PMC6609901.
Copy Download .nbib Format: NLM
Foundations of data-driven medicinal chemistry.

Future science OA

Bajorath J.
PMID: 30271612
Future Sci OA. 2018 Jun 28;4(8):FSO320. doi: 10.4155/fsoa-2018-0057. eCollection 2018 Sep.

No abstract available.

Cite
Bajorath J. Foundations of data-driven medicinal chemistry. Future Sci OA. 2018;4(8):FSO320doi: 10.4155/fsoa-2018-0057.
Bajorath, J. (2018). Foundations of data-driven medicinal chemistry. Future science OA, 4(8), FSO320. https://doi.org/10.4155/fsoa-2018-0057
Bajorath, Jürgen. "Foundations of data-driven medicinal chemistry." Future science OA vol. 4,8 (2018): FSO320. doi: https://doi.org/10.4155/fsoa-2018-0057
Bajorath J. Foundations of data-driven medicinal chemistry. Future Sci OA. 2018 Jun 28;4(8):FSO320. doi: 10.4155/fsoa-2018-0057. eCollection 2018 Sep. PMID: 30271612; PMCID: PMC6153455.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 652 entries